Costs of skin and skin structure infections due to Staphylococcus aureus: An analysis of managed-care claims

Current Medical Research and Opinion

Volumn 24, Issue 10, 2008, Pages 2821-2828

  Marton, Jeno P ^a   Jackel, Juliana L ^b   Carson, Robyn T ^a   Rothermel, Constance D ^a   Friedman, Mark ^b   Menzin, Joseph ^b  

^a PFIZER INC   (United States)

^b Boston Health Economics Inc   (United States)

Author keywords

Economics; Healthcare costs; Skin infections; Staphylococcus aureus

Indexed keywords

ANTIBIOTIC AGENT; DAPTOMYCIN; LINEZOLID; VANCOMYCIN;

ADULT; AGE; AGED; ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; COMORBIDITY; DATA BASE; DRUG COST; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HEALTH CARE COST; HEALTH INSURANCE; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; MEDICAL SERVICE; NONHUMAN; OSTEOMYELITIS; OUTPATIENT; RETROSPECTIVE STUDY; SKIN INFECTION; SKIN STRUCTURE; STAPHYLOCOCCUS AUREUS; TREATMENT DURATION;

ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; COSTS AND COST ANALYSIS; FEMALE; HOSPITALIZATION; HUMANS; INSURANCE CLAIM REVIEW; MALE; MIDDLE AGED; MODELS, THEORETICAL; RETROSPECTIVE STUDIES; STAPHYLOCOCCAL SKIN INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 55549121599     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/03007990802365169     Document Type: Article

References (13)

1. Nichols RL. Optimal treatment of complicated skin and skin structure infections. J Antimicrob Chemother 1999;44 (Suppl A):19-23
2. Martone WJ, Nichols RL. Recognition, prevention, surveillance, and management of surgical site infections: introduction to the problem and symposium overview. Clin Infect Dis 2001;33 (Suppl 2):S67-S68
3. McCaig LF, McDonald LC, Mandal S, et al. Staphylococcus aureus-associated skin and soft tissue infections in ambulatory care. Emerg Infect Dis. 2006;12:715-23
4. Chambers HF. The changing epidemiology of Staphylococcus aureus? Emerg Infect Dis. 2001;7:178-82
5. Division of Healthcare Quality Promotion, National center for Infectious Diseases, Centers for Disease Control and Prevention (CDC), US Department of Health and Human Services. National Nosocomial Infections Surveillance (NNIS) System report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004;32:470-85
6. Ploy MC, Grelaud C, Martin C, et al. First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital. Lancet 1998;351:1212
7. Fung HB, Chang JY, Kuczynski S. A practical guide to the treatment of complicated skin and soft tissue infections. Drugs 2003; 63:1459-80
8. Panlilio AL, Culver DH, Gaynes RP, et al. Methicillin-resistant Staphylococcus aureus in US hospitals, 1975-1991. Infect Control Hospital Epidemiol 1992;13:582-6
9. Marton JP, Menzin J, Sussman M, et al. The clinical and economic burden of complicated skin and skin structure infections due to Staphylococcus aureus: findings from a national database. Value in Health 2007;10:A165-A166
10. McKinnon PS, Carter C, Girase MS, et al. The economic effect of oral linezolid versus intravenous vancomycin in the outpatient setting: the payer perspective. Managed Care Interface. 2007;20:23-34
11. Lew DP, Waldvogel FA. Osteomyelitis. New Engl J Med 1997; 336:999-1009
12. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83
13. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-9